Table 3.
Antibiotics administered to participants before BSI.
| BSI Group (N = 48) | Non-BSI Group (N = 36) | p | |
|---|---|---|---|
| Antibiotics during the last 3 months | 1 (2) | 0 (0) | - |
| Antibiotics during hospitalization prior to infection | 48 (100) | 36 (100) | - |
| Use of Carbapenems | 22 (45) | 19 (53) | 0.660 |
| Use of Antipseudomonal Penicillins | 13 (27) | 9 (25) | 0.155 |
| Use of Quinolones | 24 (50) | 18 (50) | - |
| Use of Cephalosporins 3d generation | 23 (48) | 12 (33) | 0.263 |
| Use of Ceftarolin | 20 (42) | 12 (33) | 0.500 |
| Use of Colistin | 25 (52) | 16 (44) | 0.516 |
| Use of Tygecycline | 21 (44) | 19 (52) | 0.509 |
| Use of Aminoglycosides | 7 (15) | 3 (8) | 0.504 |
| Gram (+) antibiotics | 35 (73) | 29 (80) | 0.446 |
| TMP/SMX | 10 (20) | 15 (42) | 0.551 |
| Use of CAZ-AVI | 9 (19) | 2 (6) | 0.105 |
Data is presented as median (25%, 75% quartiles) or n (%); BSI, Blood Stream infection; TMP/SMX, trimethoprim-sulfamethoxazole; CAZ-AVI, ceftazidime-avibactam; Gram (+) antibiotics, teicoplanin, daptomycin, vancomycin, and linezolid; p, comparison between the two groups. Results by univariate analysis, chi square test, or Fisher’s exact test for categorical variables and by Mann–Whitney U test for continuous variables.